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Introduction  
The cornea is constantly exposed to minor trauma from dust and other objects in the 
environment. However, the vast majority of these insults go un-noticed because of the excellent 
protective and restorative properties of the ocular surface.  
 
A healthy ocular surface is one with a normal tear film, absence of adnexal disease e.g. 
meibomitis / blepharitis, and normal corneal sensation. However, in some individuals, a 
seemingly minor insult to the cornea (which in most people would heal spontaneously) does not 
heal, but results in a corneal ulcer, which is one of the leading causes of corneal blindness. Most 
of these patients appear to have a normal ocular surface on clinical evaluation. It is assumed that 
the bacterial load present on the object causing the trauma (mud / plant branch, etc.) is so high as 
to be the cause of the corneal ulcer in these patients.  However, it is possible that there may be 
additional risk factors in these individuals that are sub-clinical, which diminished the natural 
immunity of the cornea against corneal infections. Additionally, duration of treatment and the 
time taken for the ulcer to heal may be prolonged in the presence of an abnormal ocular surface. 
 
We propose to perform a case-control study of the ocular surface features of tear film, 
corneal sensation and adnexal disease to determine if these are relevant as risk factors for a 
corneal ulcer. 
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Aim of the study 
 
To study prevalence of ocular surface risk factors in a patient with corneal ulcer compared to an 
age, sex and diabetes matched cohort of patients with no corneal ulcers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
Objectives of the study 
 
Primary objective 
a. To determine if decreased corneal sensation as objectively measured using Cochet-
Bonnet aesthesiometer is a risk factor for developing corneal ulcers. 
 
Secondary objectives 
a. To determine if adnexal inflammatory conditions (blepharitis and meibomitis) are risk 
factors for developing a corneal ulcer. 
b. To determine if tear film abnormalities are risk factors for developing corneal ulcers 
using  
i. Schirmers tests   
ii. Tear film break up time 
c. To find a cut-off value of corneal sensation as measured with the Cochet-Bonnet 
aesthesiometer, with sufficient sensitivity and specificity as to be a useful risk factor 
indicator for development of corneal ulcers. 
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REVIEW OF LITERATURE 
Corneal anatomy and physiology  
The cornea is the first refracting structure in the visual process. In order to perform its 
function, it must be transparent and provide a protective interface with the environment. These 
functions are provided by a highly specialized sub-structural organization (1). 
 
Corneal blindness 
Blindness continues to be one of the major public health problems in developing 
countries. 
According to the World Health Organization, corneal diseases are among the major 
causes of vision loss and blindness in the world today, after cataract and glaucoma (2). In India, 
it is estimated that there are approximately 6.8 million people who have vision less than 6/60 in 
at least one eye due to corneal diseases; of these, about a million have bilateral involvement 
(3,4). It is expected that the number of individuals with unilateral corneal blindness in India will 
increase to 10.6 million by 2020. According to the estimates of the National Program for 
Control of Blindness (NPCB), there are currently 120,000 corneal blind persons in the country. 
According to this estimate there is an addition of 25,000-30,000 corneal blindness cases every 
year in the country. The burden of corneal disease in our country is reflected by the fact that 
90% of the global cases of ocular trauma and corneal ulceration leading to corneal blindness are 
found in developing countries (5). 
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Avoidable corneal blindness 
 The term “avoidable” encompasses preventable and treatable causes. The Andhra 
Pradesh Eye Disease Study (APEDS) reported that a significant burden of corneal blindness in 
the rural population of Andhra Pradesh was avoidable (6). Of the 0.66% prevalence of corneal 
blindness in at least one eye in this population, nearly 95% was avoidable. The avoidable causes 
of corneal blindness reported in this study were keratitis in childhood, trauma, aphakic bullous 
keratopathy, severe astigmatism post cataract surgery, keratitis in adulthood and traditional eye 
medicines.  
Based on a metaanalysis of seven population-based studies from 2001 to 2010, the true 
prevalence of corneal blindness in the Indian population is 0.45% (95% CI: 0.27-0.64%)  (7). 
Corneal conditions that are amenable to primary prevention include measles infection, 
Vitamin A deficiency, ophthalmia neonatorum, Trachoma, ocular trauma, the use of harmful 
traditional eye medication remedies and congenital Rubella syndrome. Corneal blindness 
resulting due to these diseases can be completely prevented by institution of effective preventive 
or prophylactic measures at the community level. 
Treatable or curable blindness can be tackled by an effective and accessible health care 
service delivery network. In cases such as corneal ulceration and selected cases of corneal 
scarring, sight can be restored with timely and prompt management. The prompt diagnosis and 
appropriate treatment of corneal ulceration and the easy availability of antibiotics and anti-
fungals, even in rural areas, should be the aim of community health programs. Many of those 
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who are currently blind from corneal diseases, can be visually rehabilitated by corneal 
transplantation. Penetrating keratoplasty is the most effective and most often performed solid 
organ transplantation. It is estimated that 50% of corneal blindness is treatable (8). 
The economic burden due to corneal blindness has not been extensively studied. It has 
been estimated that if strategies are implemented successfully to prevent 90% of the preventable 
blindness due to corneal disease by 2020, blindness in an additional 3.6 million persons in 2020 
and 29 million blind-years would be prevented (9). 
 
Corneal ulcer 
A corneal ulcer is a discontinuation in epithelium with destruction, and inflammation of 
the underlying stroma. It may be caused by infectious organism or may be a sterile 
inflammation.  
Microbial keratitis or infectious corneal ulcer is due to the proliferation of 
microorganisms (including bacteria, fungi, viruses, and parasites) and it’s associated 
inflammation and tissue destruction in the corneal tissue. It is a potentially sight-threatening 
condition. 
Bacteria are the most common cause of suppurative corneal ulceration. This condition 
occurs in the normal eye only relatively rarely, because of the natural resistance of the human 
cornea to infection. However, predisposing factors including contact lens wear, trauma, corneal 
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surgery, ocular surface disease, systemic diseases, and immunosuppression may alter the 
defense mechanisms of the ocular surface and permit bacteria to invade the cornea. 
Identification of the risk factors for ocular infection and assess the distinctive corneal findings 
helps to determine potential etiologies. 
When a corneal ulcer develops, appropriate  clinical and laboratory tests are performed. 
Based on the findings of these tests, a therapeutic plan can then be initiated. It is sometimes 
necessary to modify the therapeutic plan based on clinical response and tolerance of the 
antimicrobial agents. The goals for treating bacterial keratitis are to treat the corneal infection 
and associated inflammation, and to restore corneal integrity and visual function. 
The final outcome depends on the preceding pathology and the extent of ulceration at the 
time of presentation. Surgery may be considered if medical therapy fails to eradicate the 
pathogens or if the vision is markedly threatened by the infection or resultant scar. 
 
Incidence 
Corneal ulceration is a significant cause of corneal blindness (5). With the decrease in 
trachoma and other traditional causes of blindness, such as onchocerciasis and leprosy 
worldwide, the World Health Organization has recognized that corneal blindness resulting from 
microbial keratitis is in fact emerging as an important cause of visual disability (10). 
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The incidence of infectious keratitis is a variable phenomenon since there are multi-
factorial issues that include a mixture of different factors, such as geographical and other 
location-related factors, degree of development of the country concerned, the predominant 
predisposing factors and the type of infection prevalent in the community. 
It is widely accepted that bacterial and fungal keratitis have far higher incidence in the 
developing world than that in the developed world (10,11). Viral keratitis, on the other hand, is 
more prevalent in developed countries, such as the United States where Herpes Simplex 
Keratitis (HSK) is considered the leading cause of corneal blindness (12,13). However, presence 
of bacterial (14,15) and fungal (16–18) keratitis in developed countries has also been reported. 
Corneal ulceration has been recognized as a silent epidemic in developing countries, 
especially the South-east Asia Region (19). By extrapolation of Indian estimates of the 
incidence of corneal ulcer, approximately 1.5-2 million people develop corneal ulcer 
annually in our country. 
Gonzales et al. estimated that the annual incidence of corneal ulceration in Madurai 
District of South India was 1130 per million population (20). 
In a study by WHO South East Asia Regional Office in New Delhi (WHO/SEARO), it 
was estimated that 6 million corneal ulcers occur annually in the 10 countries of South East 
Asian Region encompassing a total population of 1.6 billion (21). These estimates are based on 
data from these 4 countries where the incidence of corneal ulcer ranged from 113 per 100, 000 
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in India to as high as 799 per 100,000 in Nepal (22). In contrast, in USA, corneal ulcer was 
estimated at 2 to 11 per 100,000 over a 38 year study period in Olmsted country, Minnesota 
(23). 
Treating corneal blindness following development of corneal ulcer is difficult. Therefore 
public health prevention programmes are the most cost-effective means of decreasing the global 
burden of corneal blindness (5). 
Epidemiology  
AGE  
50% of the patients with corneal ulcers were in the age group between 36 and 65 years 
and 13.3% were in the paediatric age group (24).  
Also in a study by Kesav et al 12.76% were <30 years of age, 22.87% were 30-60 years 
of age and 64.36% were >60 years of age (25).  
Microbial keratitis occurs most frequently in the middle decades of life (30 – 60 years) 
(26). 
 
Gender  
In a study by Srinivasan M et al 61.3% were males and 38.7% were females with 
ulceration occurring in both groups most frequently in the middle decades of life. The 
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predominance of corneal ulceration in males was most pronounced in the middle years with an 
overall ratio of male to female patients of 1.6 to 1 (26). 
Study by Kesav et al showed that among the patients with corneal ulcer 64.36% were 
males and 35.73% were females (25). 
Thus males and patients above the age of 60 years showed greater frequency of corneal 
ulcer. 
 
Natural defense mechanism (27)  
The natural defenses include the eyelid, tear film, corneal epithelium, and normal ocular 
flora. Microbial keratitis usually occurs in patients with predisposing factors, which can 
compromise normal ocular surface defenses. 
 
Eyelids 
The eyelids and adnexae provide a physical barrier to the ocular surface against noxious 
external irritations and exogenous microorganisms. Normal blinking also provides a good 
distribution of tear film to wash away such organisms. Eyelid trauma or any abnormality of the 
lid closure can compromise this defense mechanism. Older individuals and debilitated or 
unconscious patients with poor Bell reflexes or with poor blinking and corneal exposure are at 
risk for bacterial keratitis.  
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Tear film 
The tear film coats the anterior corneal surface.  This protects the cornea from dehydration 
and also helps in maintaining the smooth epithelial surface. The volume and thickness of the tear 
film are about 6.5 µL and 7 µm, respectively. 
The tear film is made up of three layers: the superficial lipid layer (≈0.1 µm), an aqueous 
middle layer (≈7 µm), and the mucinous layer (0.02– 0.05 µm). Most of the total volume of the 
tear film is water, approximately 98%. However, the tears also contain many biologically 
important molecules and ions, including electrolytes, lysozyme, albumin, lactoferrin, glucose, 
immunoglobulins, and oxygen. In addition, it contains a wide variety of biologically active 
substances such as growth factors, histamine, cytokines and prostaglandins. Thus, in addition to 
being a lubricant and a source of nutrients for the corneal epithelium, the tear film also serves as 
a source for regulatory factors that is required for epithelial maintenance and repair. Additional 
protection is also provided by the rinsing action of the tears.  
Abnormalities of any of the tear components, the tear volume, or the tear drainage system 
will result in a compromised ocular surface. Many of the proteins in the tear film, for instance, 
the secretory immunoglobulins, the complement components, or the  various enzymes including 
lysozyme, orosomucoid, ceruloplasmin, lactoferrin,and the betalysins, have antibacterial effects 
(28). 
The Meibomian glands and other secretory glands of the eyelid produce the components 
of the superficial lipid layer of the tear film. The aqueous layer is secreted by the lacrimal gland 
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and as well as the accessory lacrimal glands, while the mucinous layer is largely produced by 
the conjunctival goblet cells present in the conjunctival epithelium.  
Thus classification of hypo-lacrimation (dry eye syndrome) is classically divided into 
three categories that are attributable to deficiency of the lipid, aqueous, or mucin components. 
 
Tear layer Origin  Components  Physiological functions 
Lipid layer 
 
Meibomian glands 
Accessory glands 
Wax 
Cholesterol 
Fatty acid esters 
Lubrication 
Prevention of evaporation 
Stabilization 
Aqueous  
layer 
Lacrimal gland 
Accessory gland 
Water 
Electrolytes 
Proteins 
Immunoglobulins  
Lubrication 
Antimicrobial 
Bacteriostasis 
Supply of oxygen and nutrients 
Mechanical clearance 
Regulation of cellular funtions 
Mucinous  
layer 
Conjunctival goblet cells 
Conjunctival epithelial  
cells 
Corneal epithelial cells 
Sulfomucin 
Cyalomucin 
MUC1 
MUC4 
MUC5AC 
Lowering of surface  
tension,  
Stabilization of aqueous layer 
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Chronic colonization and infection of the eyelid margin or lacrimal outflow system can 
predispose the cornea to bacterial infection when minor trauma occurs. Chronic epiphora due to 
nasolacrimal duct obstruction can lead to diminished concentrations of certain antibacterial 
substances in the tear film. More commonly, a dry eye with aqueous deficiency and poor corneal 
wetting from rheumatologic diseases, HIV infection, and conjunctival scarring predisposes the 
cornea to bacterial invasion. Deficiency of the mucin or lipid layers in the tear film can also 
facilitate corneal infection. 
 
Corneal epithelium 
An intact corneal epithelium is an important defense factor. A few bacteria, such as 
Neisseria gonorrhoeae, Corynebacterium diphtheriae, Haemophilus aegyptius, and Listeria 
monocytogenes can penetrate an intact corneal epithelium, while others cannot. Compromised 
corneal epithelial integrity caused by contact lens wear, corneal trauma, or corneal surgery is the 
important predisposing factor to bacterial ulcers. Furthermore, corneal epithelial cells are 
capable of phagocytosis and intercellular transport of ingested particles, potentially providing 
additional defenses to eradicate the invading microorganisms.  
 
Normal flora 
Normal conjunctival flora includes both planktonic bacteria suspended in the tears and 
sessile bacteria adherent to the ocular surface, which help to prevent overgrowth of exogenous 
organisms. Inappropriate use of topical antibiotics could eliminate the natural protection provided 
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by normal flora and predispose the cornea to development of opportunistic infections, 
particularly when combined with corneal disease or trauma.  
The biofilm, a slimy layer composed of organic polymers produced by bacteria on 
contact lenses, can protect adherent bacteria from antibacterial substances and provides a nidus 
for infection. The conjunctiva contains sub-epithelial mucosal-associated lymphoid tissue 
(MALT), which is a collection of lymphoid cells, and can provide specific immune mediated 
defenses to the ocular surface.  
Other local corneal pathologies that predispose to corneal infection include bullous corneal 
edema from corneal injury or surgery, absence of corneal sensation from herpetic corneal 
infection or topical anesthetic abuse, and local immune-suppression from prolonged use of 
topical corticosteroids. 
 
Risk factors 
Trauma, including chemical and thermal injuries, foreign bodies, and local irradiation can 
predispose to bacterial keratitis. This is more likely in cases of corneal trauma associated with an 
agricultural rather than an industrial setting. Exposure to contaminated water or other solutions 
following corneal trauma can lead to bacterial keratitis.  
Chronic abuse of topical anesthetics can disrupt the corneal epithelium and render it at 
risk for microbial infection. Crack cocaine smoking has also been associated with corneal 
infection, probably caused by disrupting corneal epithelium via associated cellular and neuronal 
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toxicity. Nosocomial corneal infections have occurred in unconscious patients during general 
anesthesia or coma as a result of lagophthalmos and corneal exposure. Geographic and climatic 
factors can also influence the prevalence of bacterial keratitis. The variation of habitats and 
microorganism exposure, such as living in rural versus urban areas, can lead to differences in 
infectious keratitis profile. 
Contact lens use - Contact lens wear has been identified as the most common risk factor for 
bacterial keratitis in developed countries. Bacteria can adhere to a contact lens regardless of lens 
materials and microbes can survive in the moist chamber of a contact lens case. Worn contact 
lenses with surface protein and mucin deposits or irregularities are more susceptible to bacterial 
adhesion. The polysaccharide layer of encapsulated bacteria can facilitate colonization of the 
contact lens surface. A biofilm can protect bacteria from antibacterial agents. Extended wear 
contact lenses augment the risks of infection by accumulating coatings or debris under the lens 
and by enhancing bacterial colonization on the cornea. 
Contact lens use can adversely affect the healthy cornea by causing hypoxia and altering 
epithelial hemostasis. Corneal hypoxia and related endothelial dysfunction can result in acute 
epithelial edema and compromised epithelial integrity. A tight lens syndrome can be precipitated 
by poor lens hydration, inadequate oxygen permeability of the lens, and repeated overnight 
hypoxic stress. Contact lens wear slows corneal epithelial hemostasis by suppressing cell 
proliferation, impairing cell migration, and reducing the rate of cell exfoliation. Corneal abrasion 
may occur during lens insertion or removal. 
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Ocular surface pathologies - Ocular surface diseases such as cicatricial pemphigoid, Stevens-
Johnson syndrome, atopic keratoconjunctivitis, radiation and chemical injury, and vitamin A 
deficiency can lead to squamous metaplasia of the ocular surface epithelia and cause an unstable 
tear film. Disruption of the epithelial glycocalyx leads to ocular surface breakdown that 
encourages bacterial adherence and subsequent keratitis. Bacterial keratitis can complicate 
corneal epithelial erosions associated with corneal epithelial basement membrane dystrophy, 
lattice corneal dystrophy, and vernal or atopic keratoconjunctivitis.  
Bacterial keratitis after corneal transplantation can occur at any time postoperatively and 
post-keratoplasty use of extended wear soft contact lenses has been a major risk factor. Other 
predisposing factors include chronic epithelial defects, frequent application of topical 
corticosteroids and other agents, and concurrent dry eye syndrome, Loose, broken, or exposed 
sutures and suture removal can drag surface microorganisms into the corneal stroma.  
Bacterial keratitis has been reported after refractive surgeries such as radial keratotomy 
and LASIK occur shortly after surgery or several years later. In addition to the common 
organisms associated with refractive surgeries, unusual microbes such as Mycobacterium have 
been encountered in LASIK with higher frequency. Systemic conditions such as malnutrition, 
diabetes, collagen vascular diseases, or chronic alcoholism may also compromise the ocular 
surface and increase the risk of microbial keratitis caused by unusual organisms such as 
Moraxella. In patients with acquired immunodeficiency syndrome (AIDS), microbial keratitis 
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does not appear to be more prevalent than in the normal population. However, the keratitis tends 
to be more severe and more resistant to therapy in these patients. 
 
Studies on risk factors  
The epidemiological pattern of corneal ulceration varies significantly from country to 
country and even from region to region. In order to develop a comprehensive strategy for the 
diagnosis, treatment, and ultimately for the prevention of corneal infections, the aetiological 
factors predisposing to ulceration and the pathogenic organisms which are responsible must be 
determined. 
In a study by Keshav et al, of the relevant eye conditions predisposing to corneal ulcer it 
was found that about 45 patients (24%) had undergone intraocular surgery one time or other 
before the development of ulcer. 15 patients (8%) showed trichiasis, 29 patients (15.4%) showed 
corneal degeneration, 11 cases (5.85%) had history of trauma, 4 patients (2.12%) had history of 
contact lens wear, 3 patients (1.59%) were on topical steroids, glaucoma was present in 27 
patients (14.36%) and 5 patients had corneal opacity, 2(1%) patients had proptosis and 7 patients 
(3.72%) had blepharitis (25). 
A study by Srinivasan et al, a history of recent injury to the cornea mainly agricultural 
and animal products was obtained in 284 (65.4%) of the 434 patients. Other complicating 
conditions predisposing to corneal ulceration were present in 65 (15.0%) of the 434 patients 
which included chronic dacryocystitis in 19 patients and a mucocele in 1 patient, leprosy in 8 
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patients, non-leprous lagophthalmos in 7 patients, Bell’s palsy with exposure  keratitis in 2 
patients, ectropion in 1 patient, coma in 1 patient, severe blepharitis in 2 patients, and 
keratoconjunctivitis sicca in 1 patient. 8 patients had corneal anaesthesia following herpes 
simplex or herpes zoster infections, and 1 patient had neurotrophic keratitis for other reasons. In 
addition, 4 patients were diabetic, 9 patients had climatic droplet keratopathy, and 1 had band 
shaped keratopathy (26). 
Conditions such as leprosy, lagophthalmos, dry eyes, exposure keratitis, loss of corneal 
sensation from numerous causes, and climatic droplet keratopathy were likely to compromise 
corneas sufficiently to allow development of an ulcer. 
Rahmi et al, in a study done in Iran, found that the predominant predisposing factor for 
corneal ulcer was trauma, which was present in 39% of cases, followed by ocular disease (35%), 
together comprising three-fourths of all cases. Ocular disease included dry eye syndrome, 
blepharitis, lid disorders, and bullous keratopathy. Previous ocular surgery on the same eye 
included corneal grafts and trabeculectomy (9.8%), contact lens (9.8%) (29). 
 
Factors evaluated in this study and how they might predispose to development of corneal 
ulcer : 
1. Corneal sensitivity 
2. Meibomitis  
3. Blepharitis 
29 
 
4. Tear film parameters 
a. Schirmers test 
b. Tear film break up time 
 
CORNEAL SENSITIVITY 
Ocular surface sensations arise from activation of sensory nerve afferents; corneal 
afferents are derived from the anterior ciliary branches of the ophthalmic division of the 
trigeminal nerve(1) and those supplying the conjunctiva have additional sources via the nerves 
of the lids, including the naso-ciliary, lacrimal, frontal, and infraorbital nerves (30). Sensory 
axon terminals (“free nerve endings”) are present in the corneal and conjunctival epithelium. 
Electrophysiological studies suggest corneal sensory receptors show differential sensitivity to 
mechanical, thermal, and chemical stimulus modalities (30,31). The contribution of each 
receptor type to different sensations at different locations is unclear. Corneal sensations are 
found to be greatest in the central cornea. However in elderly patients cornea is more sensitive 
in the periphery, decreases as distance increases from the limbus, falls with increasing age (32). 
The trigeminal nerve is vital for maintaining corneal homeostasis and normal wound 
healing. Sensory denervation at any point along the nerve leads to reduced or absent corneal 
sensation, causing neurotrophic keratitis, which is not common but can be sight threatening. 
The measurement of ocular surface sensitivity is a useful indicator of corneal physiology 
in various corneal disease (33), following refractive surgery (34),  during wound healing, and in 
contact lens wear (35,36).  
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Acquired causes of reduced or absent corneal sensation include viral infection (herpes 
simplex and herpes zoster keratitis), chemical injury (including topical anesthetic abuse), 
trauma, fifth nerve compressive lesions, diabetes mellitus, corneal surgery, and leprosy (37,38). 
Reduction in corneal sensations was also noted in patients with dry eye disease (39). 
The corneal sensitivity is 300–600 times more than that of the skin (40).  In addition to 
serving  a protective function, the corneal nerves also regulate the  corneal epithelial 
proliferation, integrity as well as wound healing (41). In patients with diabetes, corneal 
sensitivity is reduced (42), due to a loss of corneal nerve fibers, which leads to corneal 
keratopathy (43,44)  and a susceptibility to injury, with recurrent erosions and ulcers (45). These 
changes are analogous to the diabetic foot, but since the cornea is not exposed to high pressure 
points, ulceration very rarely occurs.  
Corneal sensation can be reduced in the presence of an ulcer with no neurotrophic 
keratitis. It is thus critical to test sensation of the cornea in an unaffected area and compare with 
the contralateral side. Checking sensation in any corneal defects is essential, especially when no 
other predisposing risk factors are found, because absent corneal sensation is a sinister sign. 
Measurement of corneal sensation 
a. Qualitative measurement –  
This is done with the help of cotton wisp and recorded as normal, reduced or absent. This 
is what is most commonly done in a clinical situation. 
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b. Quantitative measurement –  
This is recorded with the aid of various instruments. It is usually used for research 
puposes. Various instruments that are available are : 
i. Noncontact:  Using air puff technique 
ii. Chemical stimulation:  Using capsaicin 
iii. Thermal stimulation: Using a carbon dioxide laser 
iv. Mechanical stimulation:  Using Cochet Bonnet aesthesiometer 
v. Electro mechanical stimulation: Using corneal Larson – Millodot aesthesiometer 
 
Historically, touch sensitivity of the ocular surface was initially measured using a von Frey 
aethesiometer. Later the Cochet-Bonnet aesthesiometer was used. Here, a mechanical stimulus 
using hair or nylon filaments of varying length and diameter is delivered (46–48). The stimulus 
applied is inversely proportional to filament / hair length, assuming that the amount of bend in 
the filament is consistent (49). Thus, the longer the length of the filament that is reported as felt 
by the patient, the better is the corneal sensitivity. 
 
The Luneau Cochet-Bonnet Aesthesiometer  
This instrument is designed for objective, rapid corneal sensitivity examinations. The 
Aesthesiometer is based upon the principle of pressure transmitted axially by a nylon 
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monofilament, of known diameter but of variable length, for a given bending stress. The length 
of the thread like mono-filament, controlled by the forefinger, ranges from 60mm to 5mm. As 
the length is decreased the pressure transmitted is increased from 11mm/gm to 200mm/gm. A 
scale on the Luneau Cochet Bonnet Aesthesiometer instrument indicates the length of the 
monofilament and is easily read during the measurement. When not in use, the tip of the 
monofilament is fully retracted into the instrument body, protecting it against damage (50,51).  
 
Steps for using the Cochet – Bonnet aesthesiometer: 
a. Extend the filament to its full length of 60 mm 
b. Retract the filament in 5 mm steps until the patient reports feeling its contact 
c. Record the filament length at this point. 
d. Repeat steps (a – c) in each of the 4 corneal quadrants: superior, temporal, inferior, nasal 
e. Sterilize the filament and retract back into the device to protect it from damage 
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FIGURE A - COCHET BONNET AESTHESIOMETER 
 
 
 
FIGURE B - MANUFACTURE PROVIDED READING 
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FIGURE C – TECHNIQUE OF MEASURING CORNEAL SENSATION  
 
 
Meibomitis (28) 
The Meibomian glands, found in the upper and lower eyelids, are modified sebaceous 
glands that secrete sebum. Sebum contains squalene, triglycerides, free fatty acids, wax esters 
and cholesterol.  
There are 30 - 40 Meibomian glands in the upper lid and 20 - 30 glands in the lower lid. 
They are arranged in a single row that is perpendicular to the eyelid margin. They span the full 
thickness of the tarsal plate. Their orifices lie posterior to the eyelashes, just in front of the 
muco-cutaneous junction. The glands form grapelike clusters that are yellowish in gross 
appearance. There is a main duct with which up to 30 - 40 saccular acini communicate. Four to 
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six layers of at least partially keratinized cells line the ducts. The acinar cells are however, non-
keratinized. These cells differentiate in a centripetal direction, with the innermost cells 
degenerating in order to form the holocrine lipid secretion. The Meibomian glands are 
surrounded by the dense collagen of the tarsus, as well as fibroblasts and lymph spaces. There is 
also a network of nerves and blood vessels that surrounds the glands. Additionally, elastic tissue, 
smooth muscle fibers, as well as portions of the orbicularis oculi are intimately associated with 
the glands. 
The lipid layer of the pre-ocular tear film is produced by the Meibomian glands and has 
the following important functions:  
1. It retards evaporation of the tear film.  
2. It helps prevent contamination of the tear film by acting as a barrier to cutaneous sebum.  
3. It decreases the surface tension of tears, thus allowing water to be drawn in, and thereby 
thickening it.  
4. It provides a seal between the upper and lower lid margins during sleep.  
5. It provides a smooth optical surface, which is critical for optimal visual acuity 
6. It enhances spread and stability of the tear film.  
7. It prevents tear spillover along the lid margin 
 
Disorders of the lipid layer results in increased evaporation and resultant dry eye 
symptoms, in spite of normal aqueous production. 
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Patients with Meibomian gland dysfunction (MGD) have been found to present with 
hyper-keratinization of the central duct, with the excess keratin causing adherence of sloughed-
off epithelial cells leading to blockage of the gland. MGD patients therefore present with dry-
eye symptoms and chalazia. Since the lipids are lacking, the stability of the tear film is affected 
and this predisposes to the formation of corneal ulcers. Thus MGD leads to alterations in the tear 
film and ocular surface disease including dry eye and clinically apparent inflammation. 
While there is no therapy that is currently approved for the treatment meibomitis, clinical 
practice includes the use of antimicrobials, warm compresses and lid scrubs. 
 
Blepharitis 
Blepharitis is one of the most common conditions encountered in the clinical practice of 
Ophthalmology. 
It is an inflammation of the eyelids where there is redness, irritation and itchy, dandruff-
like scales formed on the eyelash base. However, more severe changes like blurring of vision, 
loss or misdirection of eyelashes, and inflammatory damage to other ocular tissues can occur. 
Touching and rubbing of the irritated area can also result in a secondary infection. The muco-
cutaneous junction, along with the follicular and glandular structures that together make up the 
complex lid margin, provides a rich environment for various diseases that afflict it. Whilst the 
lids could be the source of the initial inflammatory process, corneal and bulbar conjunctival 
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surface involvement produces the most significant symptoms and visual consequences in the 
patient. 
 
Causes of Blepharitis 
Several possible causes of blepharitis include: 
 Bacterial eyelid infection 
 Meibomian gland dysfunction (MGD) 
 Dry eyes 
 Fungal eyelid infection 
 Parasites (Demodex eyelash mites) 
 
Blepharitis is often associated with dry eyes, causing confusion; is the dry eye causing 
blepharitis or is blepharitis causing the dry eye.  
In many cases, good eyelid hygiene helps control blepharitis. This includes regular and 
frequently washing of the scalp and face, warm compresses of the eyelids and scrubbing of the 
eyelid margin. When a bacterial infection causes or accompanies the blepharitis, antibiotics and 
other medications should be prescribed. Even when treatment is successful, blepharitis may 
reccur. 
Tear film Evaluation 
Evaporative dry eye is clinically tested using the tear breakup time (TBUT). To measure 
TBUT, the patient's tear film is stained with fluorescein dye, and the tear film is observed using 
a slit-lamp,  with a broad beam of the cobalt blue illumination setting.  The TBUT is the time 
between the last blink and the appearance of the first dry spot or “hole” in the tear film. An 
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average of 3 readings should be taken.  Appearance of a dry spot consistently is the same area 
indicates a localized ocular surface irregularity as is not indicative of a tear film abnormality per 
se. 
Tear film break up time is a physiologic test that is easily done and is effective in early 
diagnosis of dry eyes. 
Normal tear break-up time is approximately10 seconds. A shortened TBUT is an 
indication of an abnormal mucin layer of the tear film.(52) 
 
 
Fluorescein strip 
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Schirmers Test 
The Schirmer test is another simple test first described in 1903 which is still commonly 
performed in the clinic to assess the aqueous tear production. There are three basic variations of 
this test as given below (53). However the most popular is the Schirmer I test which measures 
both basal and reflex tear production.  
 
Types: 
 
1. Schirmer test 1 (without topical anesthesia) : This measures basal and reflex secretion. It 
measures function of main lacrimal gland.  The irritating nature of filter paper stimulates reflex 
secretory activity of the main lacrimal gland. 
2. Variation of Schirmers test 1 (with topical anaesthesia) : This measures only the basal 
secretion. It measures function of accessory lacrimal glands (the basic secretors). 
 
3. Schirmers test 2 : This measures reflex tear secretion with nasal stimulation. 
 
Materials required: 5 X 35 mm of Schirmer's strip or Whatman filter paper no. 41 
Procedure: 
1 The eye is gently dried of excess tears 
2 The schirmer strip is folded 5 mm from one end and kept in the lower fornix at the 
junction of lateral 1/3 and medial 2/3 (do not touch cornea or lashes) 
3 The patient is asked to close the eyes (54). 
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4 Tears in the conjunctival sac will cause progressive wetting of the paper strip. 
5 After 5 minutes, the filter paper is removed and the distance between the leading edge of 
wetness and the initial fold is measured, using a millimeter ruler. 
 
 
Schirmer strip - Whatman filter paper no. 41 
 
Interpretation: 
Normal: >10 mm 
Mild-moderate Dry eyes: 5-10 mm 
Severe Dry Eyes: <5 mm 
 
In order to develop a comprehensive strategy for the diagnosis, treatment, and ultimately 
for the prevention of corneal infections, the aetiological factors predisposing to ulceration and 
the pathogenic organisms which are responsible must be determined. 
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MATERIALS AND METHODS 
This is a hospital-based study. 
 
Study design - Case Control study 
 
Study population - Patients with corneal ulcer who presented to the Department of 
Ophthalmology, Schell Eye Hospital, Christian Medical College, a tertiary care centre and 
satisfying the inclusion criteria were taken as cases. 
Controls were selected from the Ophthalmology OPD and the diabetic retinopathy screening in 
the Schell eye hospital, matching for age, sex and diabetes status.  
 
Inclusion criteria for cases 
1. Patients in the age group 18 – 70 years 
2. Patients with unilateral corneal ulcer  
 
Exclusion criteria for cases 
1. One eyed patients  
2. Previous episode of similar problem 
3. Viral corneal ulcer 
4. History of ocular and intraocular surface surgeries in any of the eyes 
5. Bilateral corneal ulcers 
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6. Degenerations and Dystrophies of the cornea 
7. History of Hansen’s disease 
8. Contact lens wear 
9. Use of anaesthetic drop last 6 hours 
10. History of chronic use of any eye-drops e.g. anti-glaucoma treatment, lubricants 
11. Patients on only diet control for diabetes mellitus 
12. Mentally challenged or un co-operative patients   
 
Controls were sex, age and diabetic-status matched patients who had come for other complaints. 
 
Inclusion criteria for controls 
1. Patients in the age group 18 – 70 years 
2. Patients with no history or signs of corneal ulcer  
 
Exclusion criteria for controls 
1. History of ocular and intraocular surface surgeries in any of the eyes 
2. Degenerations and Dystrophies of the cornea 
3. History of Hansen’s disease 
4. Contact lens wear 
5. Use of anaesthetic drop last 6 hours 
6. History of chronic use of any eye-drops e.g. anti-glaucoma treatment, lubricants 
7. Patients on only diet control for diabetes mellitus 
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8. Mentally challenged or un co-operative patients   
 
Setting 
Location: Department of Ophthalmology, Christian Medical College, Vellore 
Period of Recruitment: February 2018 to July 2018. 
The principle investigator performed the data collection. 
 
Methodology 
This Case Control study was planned in the Department of Ophthalmology, Christian Medical 
College, Vellore. 
 
Step 1 : Identification of patients 
Cases - Patients who had unilateral corneal ulcer and presented to the Department of 
Ophthalmology, Christian Medical College, Vellore, who fulfilled the eligibility criteria were 
included in the study after informed consent. 
 
Controls - Patients who presented with problems other than corneal ulcer, to the Department of 
Ophthalmology, Christian Medical College, Vellore, who fulfilled the eligibility criteria were 
included in the study after informed consent 
 
Step 2 : Recruitment of subjects after informed consent  
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Step 3 : Data collection 
The following data was collected: 
1. Demographics- Age, sex 
2. History of trauma to eye, mode and material causing injury 
3. History of use of contact lens 
4. History of any medical illness – Diabetes, leprosy 
 
Cases –  
i. Assessment for meibomitis and blepharitis in the normal eye. 
ii. Measurement of corneal sensation in the normal eye.  
iii. Assessment of tear film parameters in the normal eye. 
If there was an area of uninvolved cornea in the study eye, corneal sensation was also measured 
in this eye. Data for these patients was sub-analysed.  
The uninvolved eye was taken as a surrogate of the ulcer eye to measure tear film parameters 
(tearfilm break up time and schirmers test) and to quantify corneal sensations. 
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Controls –  
i. Assessment for meibomitis and blepharitis in both the eyes. 
ii. Measurement of corneal sensation in both the eyes.  
iii. Assessment of tear film parameters in both the eyes. 
 
 
Diagrammatic Algorithm of the study  
 
iv.  
 
 
 
 
 
 
 
 
 
 
 
 
All patients presenting to the Dept. of Ophthalmology with corneal ulcer above 
18 years of age as per the inclusion and exclusion criteria enrolled after 
informed consent.  
The primary investigator took history and then evaluated for the study 
parameters as detailed above and entered in the data sheet 
If there was a 2 mm region of clear cornea in the corneal ulcer eye, corneal 
sensations was tested here as well. First the normal eye was assessed 
followed by the ulcer eye to avoid the spread of infection. 
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Age, sex and diabetes status matched controls were selected from the general 
OPD and the diabetic retinopathy screening OPD in the Schell as per the 
inclusion and exclusion criteria 
The data was collated and analysis done. 
 
After informed consent, the primary investigator took history and then 
evaluated for the study parameters as detailed above and entered in the data 
sheet 
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Statistical methods and Sample size calculation 
Epidemiology Methods - Matched Case Control Studies - Single Control per Case 
Proportion exposed in the control group  0.3 
Anticipated Odds Ratio  3 
Proportion exposed in the case group 0.56 
Power (1- beta) % 80 
Alpha error (%) 5 
1 or 2 sided 2 
Minimum no. of required discordant pairs, ' m ' 29 
No. of required pairs to detect ' m ' discordant pairs in the exposure group 55 
  
 
 
With reference to Keshav et al, the prevalence of corneal ulcer was found to 36.7% assuming 
the proportion of exposed in the control group to be 30% with an anticipated odds ratio at 3% 
for a power at 80% and alpha error at 5% for a two sided test we needed to study at least 55 
cases and 55 controls. 
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Formula: 
  
Statistical Methods: 
 Data entry was be done using EpiData 3.0.  
 Data analysis was done using SPSS. version 21 software.  
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 Descriptive statistics which are continuous (age, Schirmers with anaesthesia ) were 
reported using Mean ± SD and statistical significance was obtained with two independent 
sample t test 
 Categorical variables which include gender, diabetes, Schirmers test 1,  meibomitis, 
blepharitis were reported using Frequency and Percentage and their statistical 
significance obtained using Pearson Chi Square test/ Fishers exact test as appropriate.  
 Binary Logistics was done for to assess risk factors. 
 Receiver operating characteristic (ROC) curve was obtained to attempt to arrive at an 
ideal cutpoint of corneal sensation in controls. 
 
 
Outcome measures  
1. Quantitative measurement of corneal sensation using the Cochet - Bonnet aesthesiometer 
2. Presence or absence of eyelid margin disease – meibomitis/ blepharitis 
3. Quantitative measurements of tear break-up time and Schirmers test 1 and 2 
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RESULTS 
 
A total of 110 patients were taken in the study, which included 55 cases and 55 controls. 
The study was conducted between February 2018 and September 2018 in Schell eye hospital, 
Christian Medical College. The patients who presented with corneal ulcer were compared to a 
similar cohort of controls who are age, gender and diabetes matched. 
 
The following are the results obtained: 
 
Baseline characteristics of all the study patients are shown in Table 1 and Figures 1 and 2 
 
Table 1: Overview Of The Baseline Characteristics Of All Patients Selected For This 
Study. 
 
 
There were more number of male patients than female patients, and the mean age of recruitment 
was about 43 years of age. 
CHARACTERISTICS  CASES CONTROLS 
MALES 40 (72.70%) 40 (72.70%) 
FEMALES 15 (27.30%) 15 (27.30%) 
MEAN AGE(years) 43.44 (+/- 12.63) 43.47(+/-12.29) 
DIABETES  9 (16.40%) 9 (16.40%) 
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There is no statistical difference in baseline characteristics between cases and controls as they 
were age, gender and diabetes matched. 
 
 
FIGURE 1 – GENDER - CASES AND CONTROLS 
 
 
 
Males are more commonly affected with corneal ulcer than females. 
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FIGURE 2 – PERCENTAGE OF DIABETICS IN CASES AND CONTROLS 
 
 
 
 
 
There were 16.4 % of diabetics among the cases. 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
YES - 16.4% NO - 83.6%
%
 o
f c
as
es
 
DIABETES
DIABETES
53 
 
AFFECTED EYE 
 
Of the total of 55 cases eyes, left eye was more commonly involved than right eye, i.e., 36 
(65.50%) were left eyes and 19 (34.50%) were right eyes. The data is shown in table - 2 and 
figure 3. 
Table 2 : Frequency of eye affected in cases 
 
EYE RIGHT EYE  LEFT EYE 
PERCENTAGE 34.50% 65.50% 
 
Figure 3: Frequency of eye affected in cases 
 
 
 
0
10
20
30
40
50
60
70
RIGHT EYE - 34.50% LEFT EYE - 65.50%
%
 o
f c
as
es
 
AFFECTED EYE
AFFECTED EYE
54 
 
OUTCOME RESULTS 
 
The following comparisons were done: 
1. Between unaffected eye of cases (surrogate for the ulcer affected eye) and the same sided 
eye of the controls. 
2. Between corneal ulcer eye and the fellow unaffected eye in cases. 
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Part 1  
CASES VS CONTROLS 
 
CORNEAL SENSATION 
Corneal sensation is checked in unaffected fellow eye of the cases and compared with corneal 
sensation of the controls. The measurements were also taken in the affected eye of cases if more 
than 2 mm clear unaffected area is present. 
 
Table 3 : Corneal sensation in cases and controls 
 
 Number of eyes studied (n) Mean value of corneal sensation (standard 
deviation) 
p - value 
Cases 55 56.18 (4.406) 0.003 
Controls 55 58.45 (3.452) 
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Figure 4 : Corneal sensation in cases and controls 
 
 
 
 
The corneal sensation in the control eyes was better than in the unaffected surrogate eye of the 
cases, and this difference is statistically significant (p = 0.003).  
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Meibomitis 
Presence of meibomitis in the unaffected fellow eye of cases and in the controls was noted. The 
data is shown in table – 4 and figure – 5  
 
 
Table 4 : Frequency of meibomitis among the cases and the controls 
 
   Cases (%) Controls (%) P - value 
 
Meibomitis  
 
 
 
Total no. of eyes 55(100%) 55 (100%)  
Present 22 (40%) 15 (27.3%) 0.158 
Absent 33 (60%) 40 (72.7%) 
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Figure  5 : Frequency of meibomitis among the cases and controls 
 
 
 
 
There is no statistically significant difference of the presence of meibomitis between the cases 
and the controls (p=0.158). 
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Blepharitis  
Presence of blepharitis in the unaffected fellow eye of cases and in the controls was recorded. 
The data is shown in table – 5 and figure – 6. 
 
 
Table 5 : Frequency of blepharitis among the cases and the controls 
 
  Cases (%) Controls (%) P - value 
Blepharitis   Total no. of eyes  55 (100%) 55 (100%)  
Present  24 (43.6%) 10 (18.2%) 0.004 
Absent 31 (56.4%) 45 (81.8%) 
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Figure 6 : Frequency of blepharitis among the cases and controls 
 
 
 
 
There was more blepharitis present in affected patients as opposed to the controls, which was 
statistically significant (p=0.004). 
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Schirmers test 1 
Schirmers test 1 was done in the unaffected fellow eye of cases and in the controls. The data is 
shown in table – 6 and figure – 7. 
 
Table 6 : Schirmers test 1 in the cases and controls  
 
 cases controls p- value 
Total no. of eyes 55 (100%) 55(100%)  
 
0.000 
Normal  31(56.4%) 51(92.7%) 
Mild – moderate dry eye  20 (36.4%) 3(5.5%) 
Severe dry eye 4(7.3%) 1(1.8%) 
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Figure  7 : Schirmers test 1 in the cases and controls 
 
 
 
 
There was a highly statistically significant difference in Schirmers test 1 i.e. reflex + basal tear 
secretion, between the cases and controls (p<0.001). 
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Schirmers test with topical anaesthesia 
Schirmers test with topical anaesthesia was done in the unaffected fellow eye of the cases and in 
the controls. The data is shown in table – 7 and figure – 8. 
 
 
Table 7 : Schirmers test with topical anaesthesia in the cases and controls 
 
 Number of eyes studied Mean (standard deviation) P – value 
Cases 55 13.65 (10.129) 0.118 
Controls 55 16.25 (6.851)  
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Figure 8 : Schirmers test with topical anaesthesia in the cases and controls 
 
 
 
There is was no statistically significant difference in Schirmers test (with topical anaesthesia) 
i.e. only basal secretion, between cases and controls (p=0.118). 
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Tear film break up time 
Tear film break up time was done in the unaffected fellow eye of cases and the normal eye of 
cases and compared. The measurements are shown in table – 8 and figure – 9.  
 
 
Table 8 : TBUT in the cases and controls  
 
 Cases Controls p-value 
Total no. of eyes 55 (100%) 55 (100%)  
Normal 27 (49.1%) 37 (67.3%) 0.053 
Reduced 28 (50.9%) 18 (32.7%) 
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Figure 9 : TBUT in the cases and controls 
 
 
 
 
There is no statistically significant difference in TBUT between cases and controls (p=0.053). 
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Part 2 – Cases: Difference between affected and fellow unaffected eye 
 
Corneal sensation 
The corneal sensations were taken in the normal eye and the ulcer eye (if >2 mm of clear area 
was present) of patients and compared. The corneal sensations in the two eyes of cases are 
shown in table - 9 and figure – 10 
 
Table 9 : Corneal sensation in ulcer and normal eye of the cases 
 
 Number of eyes studied Mean value of corneal sensation 
(standard deviation)  
p - value 
Ulcer eye 49 51.63 (5.985) 0.000 
Normal eye 55 56.18 (4.406) 
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Figure 10 : Corneal sensation in ulcer and normal eye of the cases 
 
 
 
There is statistically significant difference in corneal sensation between the two eyes in cases. 
The unaffected eye had a significantly better corneal sensation (p=<0.05). 
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Meibomitis 
Presence of meibomitis in the ulcer and normal eye is looked for in cases. The data is shown in 
table – 10 and figure – 11.  
 
 
Table 10 : Frequency of meibomitis among the cases 
 
   Ulcer eyes (%) Normal eyes(%) P value 
 
Meibomitis  
 Total no. of eyes 55 (100%) 55(100%)  
0.337  Present  27 (49.1%) 22(40%) 
Absent  28 (50.9%) 33(60%) 
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Figure 11: Frequency of meibomitis among the cases 
 
 
 
There is no statistically significant difference between the two eyes in the cases. 
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Blepharitis 
Presence of blepharitis in the ulcer and normal eye is looked for in cases. The data is shown in 
table – 11 and figure – 12. 
 
 
Table 11 : Frequency of blepharitis in the cases 
 
  Ulcer eyes (%) Normal eye (%) P value 
 
Blepharitis 
Total no. of eyes 55 (100%) 55 (100%)  
0.566 Present 27 (49.1%) 24 (43.6%) 
Absent 28 (50.9%) 31 (56.4%) 
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Figure 12 : Frequency of blepharitis among the cases 
 
 
 
There was no statistically significant difference between the two eyes in the cases. 
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Schirmers test 1 
Schirmers test 1 was done in the ulcer eye and normal eye of cases and compared. The 
measurements are shown in table – 12 and figure - 13. 
 
Table 12 : Schirmers test 1 in ulcer and normal eye of the cases 
 
  Ulcer eyes (%) Normal eyes (%) P value 
Total no. of eyes  55 (100%) 55 (100%)  
 
0.000 
Normal 50 (90.9%) 31(56.4%) 
Mild- moderate dry eye 3 (5.5%) 20(36.4%) 
Severe dry eye  1(1.8%) 4(7.3%) 
Not done  1 (1.8%) -  
 
 
 
 
 
 
 
 
 
 
74 
 
 
 
 
Figure 13 : Schirmers test 1 in ulcer and normal eyes of the cases 
 
  
 
There is a statistically significant difference between the two eyes in the cases. 
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Schirmers test with topical anaesthesia 
Schirmers test 2 was done in the ulcer eye and normal eye of cases and compared.  
The measurements are shown in table – 13 and figure -  14. 
 
 
Table 13 : Schirmers test with topical anaesthesia in ulcer and normal eye of the cases 
 
 Number of eyes studied Mean (SD) p value 
Ulcer eye 54 17.96 (8.685) 0.019 
Normal eye   55 13.65 (10.129) 
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Figure 14 : Schirmers test with topical anaesthesia in ulcer and normal eye of the cases 
 
 
 
 
There is a statistically significant difference between the two eyes in the cases. 
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TBUT  
Tear film break up time was done in the ulcer eye and normal eye of cases and compared.  
 
The measurements are shown in table – 14 and figure -  15. 
 
Table 14 : TBUT in ulcer and normal eyes of the cases 
 
 Ulcer eyes  Normal eyes  P value 
Total no.  55(100%) 55(100%)  
 
0.000 
Normal 10 (18.2%) 27(49.1%) 
Reduced 28(50.9%) 28(50.9%) 
Not done 17(30.9%) 0 
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Figure 15 : TBUT in ulcer and normal eyes of the cases 
 
 
 
There is a statistically significant difference between the two eyes in the cases. 
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ROC CURVE FOR CORNEAL SENSATION :  
The following curve represents the sensitivity and specificity of corneal sensation in controls. 
 
 
 
The area under curve is 0.755 (95 % CI 0.689 – 0.822) with  p value = 0.000 which is 
statistically significant. 
With corneal sensation at a cut off point of 52.50 mm the sensitivity of the test is 95.5% and 
specificity is 36.5% for controls. 
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DISCUSSION 
Corneal ulceration is one of the most important causes of corneal blindness, especially in 
younger populations and people with low socio – economic status. The ocular surface usually 
possesses excellent mechanisms to protect the cornea against such infections. However, when 
the ocular surface is disturbed or disrupted, the risk of developing corneal ulceration increases.  
 
There are many different conditions that can damage the cornea leading to visual 
impairment and blindness. These include infectious, nutritional, inflammatory, inherited, 
iatrogenic, and degenerative conditions. Overall, in low- and middle-income countries, 
infectious keratitis tends to be the most common problem. Patients belonging to lower 
socioeconomic groups have more occupation-related trauma with vegetative matter, poor ocular 
hygiene and awareness, compromised nutritional status and less affordability and accessibility to 
medical help.  
 
There are three important elements needed to address the problem of corneal blindness: 
prevention, treatment, and rehabilitation. Prevention is the single most important step to avoid 
corneal ulceration. Prevention will reduce the number of people with blindness and also reduce 
economic burden especially in developing countries.  
 
This study was performed in order to evaluate ocular surface features in patients with 
corneal ulcer and compared to age, sex and diabetes matched individuals in order to  determine 
whether these ocular surface risk factors could be possible contributors for the development of 
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corneal ulcer. This would enable preventive steps to prevent corneal ulceration and blindness in 
predisposed patients. 
 
The required sample size of 55 cases and 55 controls that were age, gender and diabetes 
matched was obtained for this study. In the cases, the fellow unaffected eye was taken as a 
surrogate for the eye with the ulcer, with the presumption that the ocular surface parameters that 
were being studied would be similar in both eyes of an individual patient prior to development 
of the corneal ulcer. It was also theorized that these parameters would be distorted once a 
corneal ulcer developed. This was also investigated in this study.  
 
The mean age of patients with corneal ulcer in our study was 43.4 years, is similar to the 
study reported by Panda et al as well as Srinivasan et al (24,26). Males (72.7%) were more 
commonly affected than females (27.3%). These findings reflect the increased exposure to 
environmental factors in  the actively working age group of males in our population. This 
finding is consistent with those of other studies (26) done in the South Indian population.   
 
It is interesting to note that there were only 9 out of the 55 cases (16.4%) who were 
diabetic.  
 
Our study shows that a decrease in corneal sensation predisposes to development of 
corneal ulceration. 
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The corneal sensitivities in the cases were lower as compared to the controls as 
objectively measured using the aesthesiometer (56.18, SD 4.4 vs 58.45 SD 3.5). This difference 
was highly statistically significant (p – value = 0.003). The lower corneal sensation probably 
affects corneal homeostasis and defense mechanisms, thus predisposing to corneal ulceration. 
 
The presence of Meibomitis was not found to be a significant factor in this study and was 
present in 40% of cases and 27.3% of controls (p –value = 0.158). However, there does seem to 
be a clinical trend of increased meibomitis in the patients with corneal ulcers.  
 
The presence of Blepharitis however, was found to be higher in the cases (43.6%) as 
compared to the controls (18.2 %). This was a statistically significant difference (p=0.004). 
Thus, the presence of blepharitis does pose an increased risk for development corneal ulcer 
according to our study. 
 
Meibomitis and blepharitis would probably predispose to corneal ulcer due to their effect 
of disruption of the normal tear film. 
 
Schirmers test 1 is one of the tests for dry eye used in the Rheumatologic criteria for the 
diagnosis of Sjogrens syndrome. It gives a measure of the reflex as well as basal tear secretion in 
an individual. The Schirmers test 2 is performed after anaesthetizing the conjunctival sac. It 
provides a measure of the basal tear secretion. 
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In our study, the presence of dry eye in cases was found to be significantly more than in the 
controls, thus proving to be a highly significant risk factor for the development of corneal ulcer 
with a p value < 0.001. 
 
However, when comparison was done between the unaffected fellow eye and the ulcer 
eye of cases, Schirmers test 1 was not very reliable, with 90% of the ulcer eye showing a normal 
Schirmers test 1 value. This would be due to reflex tear secretion in response to the ulcer in that 
eye. 
 
Schirmers test with topical anaesthesia did not show a statistically significant 
difference in the cases and controls.  
 
The difference in the Tear film break up time between cases and controls was just short 
of statistical significance (p = 0.053).  
 
We attempted to find a “normal” value of corneal sensation from our study using the 
ROC curve below which an increased risk of corneal ulceration could be reliably predicted. 
Taking a cut off value of 52.5mm, the sensitivity is 95.5 % but specificity is only 36.5 %. So 
this cutoff may be used as a screening tool, although a high false positive rate would be 
expected. However, but this sample size was not sufficient to come to a value with sufficient 
sensitivity and specificity be give any meaningful result.  
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LIMITATIONS OF THE STUDY 
 
1. The cases in our study were mostly from a rural population and controls were not 
matched from the same population. 
 
2. The sample size was too small to derive normative corneal sensation data, and to arrive at 
a cut-off value for increased risk of developing a corneal ulcer. 
 
3. The normal unaffected fellow eye was used for the various measurements with the 
presumption that the ocular surface would be similar in both eyes in a person before 
development of a corneal ulcer. This presumption could have been wrong if there were 
unilateral conditions like mild chemical injury that could have been missed. 
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CONCLUSIONS 
 
1. Patients with corneal ulcers have a significantly decreased corneal sensation as compared 
to age, sex and diabetes matched patients with no corneal ulcer. 
2. Patients with corneal ulcers have a significantly increased incidence of blepharitis as 
compared to age, sex and diabetes matched patients with no corneal ulcer. 
3. Meibomitis may be a risk factor for corneal ulcers, though our study showed only a trend 
in this direction which did not reach statistical significance. 
4. Schirmers 1 test is significantly decreased in patients with corneal ulcers as compared to 
age, sex and diabetes matched patients with no corneal ulcer. 
5. Schirmers test with topical anaesthesia is similar in patients with corneal ulcers as 
compared to age, sex and diabetes matched patients with no corneal ulcer. 
6. Tear break up time was not found to be a statistically significant risk factor for diabetes in 
this study. 
7. A cut-off value of corneal sensation as measured with the Cochet-Bonnet aesthesiometer, 
with sufficient sensitivity and specificity as to be a useful risk factor indicator for 
development of corneal ulcers could not be determined from this study. A larger sample 
size would be needed.  
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APPENDIX - (ii) 
PATIENT INFORMATION SHEET- ENGLISH 
 
Title of the study – Case-control study for ocular surface risk factors in microbial keratitis. 
You are being invited to take part in this research study carried out in Schell eye hospital, 
Christian Medical College, Vellore. The information in this document is meant to help you 
decide whether or not to take part in this study.  
Before you decide whether or not you wish to take part, you should read the information 
provided below carefully and, if you wish, discuss it with your relatives.  Take time to ask 
questions – do not feel rushed or under pressure to make a quick decision. 
You should clearly understand the risks and benefits of taking part in this study so that you can 
make a decision that is right for you. This process is known as ‘Informed Consent’.  
You do not have to take part in this study and a decision not to take part will not effect on your 
future medical care.  
You can change your mind about taking part in the study any time you like.  Even if the study 
has started, you can still opt out.  You do not have to give us a reason.  If you do opt out, it will 
not affect the quality of treatment you get in the future.     
          
Q. 1) What is the purpose of the study? 
Our study will assess how ocular surface changes and adnexal inflammatory conditions are 
associated with the development of microbial corneal ulcer. This is compared with healthy 
normal eyes of age, sex and diabetes matched patients who do not have a corneal ulcer.  
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The tests done are routinely used for diagnostics of various eye disease and not a new tests. 
 
Q.2) Why have I been invited? 
You have been chosen because you have a corneal ulcer in one eye and taken as a case or as 
control though you do not have a corneal ulcer to match the confounding factors. 
 
Q.3) What will happen if I take part? 
If you agree to take part in the study, you will have to fill up the consent and sign it, undergo the 
routine eye examination along with the test for tear film parameters and corneal sensations by 
the principle investigator. 
 
Q.4) What about expenses and payments? 
There are no additional expenses or payments for any tests done as a part of the study. 
 
Q.5) What is the possible benefits of taking part in the study? 
If you do have ocular surface changes and adnexal inflammation they will be considered and 
appropriate measures will be taken to treat them. The causal association of each risk factor will 
be known. Your participation can benefit the future patients who developing corneal ulcer with 
underlying ocular surface risk factors. 
 
Q.6) What are the possible risks of taking part in the study? 
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There are no risks involved in taking part in this study. It might just take additional 15 minutes 
of your time. 
 
Q.7) Will my taking part in the study be kept confidential? 
All patient information is stored on password protected computer databases and in locked filing 
cabinets and will only be accessible to the research team.  
 
Q. 8) What if there is a problem? 
If you wish to complaint about any aspect of the way in which you have been approached or 
treated during the course of this study, you should contact the Principal investigator or you may 
contact Research Office, Carman Block, Bagayam, Vellore, 632002, email - 
research@cmcvellore.ac.in or researchothers@cmcvellore.ac.in, phone - 0416 2284294. 
 
Q.9) Who has reviewed this study? 
The Institutional Review Board (IRB) has reviewed this study.                  
 
You have the right to confidentiality regarding the privacy of your medical information 
(personal details, results of physical examinations, investigations, and your medical history). By 
signing this document, you will be allowing the research team investigators, if required to access 
your medical information.                     
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The results of clinical tests performed as part of this research may be included in your medical 
record. The information from this study, if published in scientific journals or presented at 
scientific meetings, will not reveal your identity. 
Thank you for reading this, 
If you agree to enter the study, please sign the attached consent form.   
 
Contact Person (Principal Investigator) 
Dr. T. Maria Priyanka , 
Department of Ophthalmology,Christian Medical College, Vellore. 
Phone: 9849725055,  
Email: priyareddyt@gmail.com 
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  PATIENT INFORMATION SHEET - HINDI 
                                                 पेशंट इ̢फ़मőशन 
 
आपको िनमंũण िदया जा रहा है, हमारे हॉİ˙टल िŢ̾चन मेिडकल कॉलेज की एक ːडी मŐ। 
ये डॉƐुमŐट मŐ जो इ̢फ़मőशन है, वो आपको ये िडसाइड करने मŐ मदत करेगी िक आपको ये ːडी मŐ भाग 
लेना है की नही।ं 
 
इससे पहले की आप िडसाइड करे की आपको भाग लेना है की नही,ं ये डॉƐुमŐट अछे से पड़े और चाहे तो 
अपने घर वालो ंसे अछे से िडˋस भी करे। 
 
आपके मन मŐ जो डाउट है, कोई Ůʲ है तो आप िबलकुल िनिʮत होकर पूछ सकते है। 
जʗबाज़ी मŐ कोई िनणŊय ना ले। 
आपको साफ़ पता होना चािहए िक इस ːडी के Ɛा įरˋ और लाभ है, तािक आप सोच समझ कर 
िनणŊय ले सके। 
इसे 'इ̢फ़ॉ̱डŊ कɌŐट' कहा जाता है। 
 
अगर आप इस ːडी मŐ भाग नही ंलेना चाहते तो इस बात का आपके इलाज पर कोई असर नही ंहोगा। 
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आप एक बार हाँ बोलने के बाद भी अपना िनणŊय बदल सकते है, ːडी के दौरान। 
आपको हमŐ कोई भी सफ़ाई देने की ज़ŝरत नही ंहै। 
 
इस ːडी का Ɛा उधेʴ है? 
आखो ंके काले पुतले पर अʤर होने से, आखो ंके बाहरी ȕचा पे Ɛा असर होता है-हमŐ यह जाँचना है। 
ये बदलाव एक नॉमŊल आँक के साथ कɼेर िकया जाएगा। कɼेįरंग के िलए एक िबना सुई वाली जाँच की 
जाएगी। यह टेː आम तौर पर करे जाते है ओपीिड मŐ। 
ये टेː आम तौर पे इˑमाल िकया जाता है, आँखो ंकी जाँच मŐ। 
 
आपको Ɛँू िनमंũण िमला है इस ːडी के िलए? 
आपको इसिलए िनमंũण िमला है, Ɛँू की आपको आँखो के काले पुतले पर अʤर है।टेː करने के व˫ 
आपका कॉनŎआ िबलकुल हील ही गया होगा और िबलकुल नोमŊल लगता होगा। 
 
अगर आप इस ːडी मŐ भाग लेते है तो Ɛा होगा? 
अगर आप इस ːडी मŐ भाग लेने के िलए रज़ामंद होते है, तो आपको एक İƑिनकल इ̢फ़मőशन शीट 
भरनी होगी, और अपनी आँको का चेक उप करके कुछ रेƶुलर टेː करने होगे। 
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आपका Ɛा ख़चाŊ होगा? 
आपको कुछ भी एƜŌ ा ख़चाŊ नही ंभरना होगा। 
 
इस ːडी मŐ भाग लेने से आपको Ɛा फ़ायदा होगा? 
अगर आपके सैɼल मŐ बदलाव िमला तो हम आपको उसके अनुसार टŌ ीटमŐट दŐगे। 
अगर कुछ बदलाव नही ंिमल पाए तो आपके इस ːडी मŐ िहˣा लेने से ͆यूचर के पेशंट्स को फ़ायदा 
होगा। 
 
इस ːडी मŐ भाग लेने से आपका Ɛा नुक़सान हो सकता है? 
आपका कुछ नुक़सान नही ंहोगा, बस पȾहा िमनट एƜŌ ा लगŐगे आपके क़ीमती समय के। 
 
Ɛा मेरे भाग लेने की इ̢फ़मőशन गुɑ रखी जाएगी? 
सारे पेशंट्स की िडटेल क̱ɗूटर डेटाबेस मŐ सुरिƗत रखी जाएगी, पासवडŊ के साथ। यह इ̢फ़मőशन िसफ़Ŋ  
इस ːडी की रीसचŊ टीम को देखने की इजाज़त होगी। 
 
अगर आपको कोई तकलीफ़ Šई रोग Ɛा कर सकते है ? 
अफ़ॉर आपको िकसी तरह की परेशानी Šई इस ːडी के दौरान, की आपकी टŌ ीटमŐट एक से नही ंŠई है तो 
आप इस ːडी के मुƥ इɋेİːगेटर यस रीसचŊ ऑिफ़स से सɼकŊ  कर सकते है। 
पता है - रीसचŊ ऑिफ़स, कारमन ɰाक,बाग़याम, वेʟूर, ६३२००२ 
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ईमेल ऐडŌ ेस है- research@cmcvellore.ac.in, researchothers@cmcvellore.ac.in 
फ़ोन नɾर - 0416-2284294 
 
इस ːडी को िवǒापन की किमटी ने परखा है? 
हाँ, हमारे इİɍटूशन के įरʩू बोडŊ ने इस ːडी को परखा है। 
आपकी पसŊनल इ̢फ़मőशन गुɑ रहे, इस बात का आपको पूरा अिधकार है।यह लेटर साइन करके, आप 
इस ːडी की रीसचŊ टीम को यह अिधकार दे रहे है की वह आपकी िडटेʧ, जाँच के įरज़ʐ, आपकी 
मेिडकल िह Ōː ी को देख सके। 
 
इस ːडी के दौरान जो भी टेː िकए जाएँगे, और जो भी टŌ ीटमŐट दी जाएगी, वह सभ कुछ आपके मेिडकल 
रेकॉडŊ मŐ शािमल िकया जाएगा। यिद इस ːडी के पįरणाम िकसी भी िवǒापन की जनŊल मŐ, यस िवǒान की 
मीिटंƺ मŐ Ůायोिजत की गयी, तो इसने आपकी पहचान गुɑ रखी जाएगी। 
 
पड़ने के िलए धɊवाद 
 
अगर आप इस ːडी मŐ भाग लेना चाहते है, तो इस लेटर से जुड़े कɌŐट फ़ॉमŊ पर साइन कर दीिजए। 
 
मुƥ इɋेİːगेटर 
डॉƃर. माįरया िŮयंका 
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आँखो ंका िडपाटŊमŐट 
िŢ̾चन मेिडकल कॉलेज, वेʟूर 
फ़ोन नɾर- 9849725055 
ईमेल ऐडŌ ेस- priyareddyt@gmail.com 
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APPENDIX - (iii) 
INFORMED CONSENT FORM FOR SUBJECTS 
ENGLISH 
 
Informed Consent form to participate in a research study  -  
Study Title : Case – Control study for Ocular surface risk factors in microbial keratitis 
 
Study Number : 
Subject’s Initials :                                   Subject’s Name : 
Date of Birth / Age :                               (Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated __________ for the 
above study and  have had the opportunity to ask questions. [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights being 
affected. [  ] 
 
(iii)  I understand that, the Ethics Committee and the regulatory authorities will not need my 
permission to look at my health records both in respect of the current study and any 
further research that may be conducted in relation to it, even if I withdraw from the trial. I 
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agree to this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published. [  ] 
 
(iv)  I agree not to restrict the use of any data or results that arise from this study provided 
such a use is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
 
Signature/ thumb impression of the Subject/Legally Acceptable or representative 
Date: ___/___/____ 
Signatory’s Name: _____________________________ 
Signature of the Investigator: _____________________ 
Date: ___/___/____ 
Study Investigator’s Name:   _____________________ 
Signature/ thumb impression of the Witness: ________ 
Date: ____/___/____ 
Name & Address of the Witness: __________________ 
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                                            िवषय के िलए सूिचत सहमित फ़ॉमŊ 
 
अनुसंधान अȯयन मŐ भाग लेने के िलए ǒात सहमित फॉमŊ - 
अȯयन शीषŊक: केस - माइŢोिबयल केरैिटस मŐ ओकुलर सतह जोİखम कारको ंके िलए िनयंũण अȯयन 
 
अȯयन संƥा: 
िवषय के आरंिभक:                             िवषय का नाम: 
जɉ ितिथ / आयु की ितिथ: 
1.  
मœ पुिʼ करता šं िक मœने उपरोƅ अȯयन के िलए ____________ के सूचना पũ को पढ़ िलया है 
और समझ िलया है और सवाल पूछने का अवसर िमला है। (  ) 
2.  
मœ समझता šं िक अȯयन मŐ मेरी भागीदारी ˢैİǅक है और मœ िबना िकसी कारण के िबना, िकसी 
भी समय िबना िकसी िचिकȖा कारण या कानूनी अिधकारो ंको Ůभािवत िकए िबना वापस लेने के 
िलए ˢतंũ šं। (  )  
3.  
मœ समझता šं िक Ůायोजक की ओर से काम करने वाले दूसरो ं(Ůायोजक की ओर से हटाना), 
एिथƛ कमेटी और िनयामक Ůािधकाįरयो ंको मौजूदा अȯयन के संबंध मŐ अपने ˢा˖ के 
įरकाडŊ को देखने के िलए मेरी अनुमित की आवʴकता नही ंहै अनुसंधान जो इसके संबंध मŐ 
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आयोिजत िकया जा सकता है, भले ही मœ परीƗण से वापस ले जाया हो। मœ इस पŠंच से सहमत šं। 
हालांिक, मœ समझता šं िक मेरी पहचान तीसरी पाटŎ के िलए जारी िकसी भी जानकारी या Ůकािशत 
मŐ Ůकट नही ंहोगी।   (  ) 
4.  
मœ इस अȯयन से उȋɄ होने वाले िकसी भी डेटा या पįरणामो ंके उपयोग को Ůितबंिधत करने के 
िलए सहमत नही ंšं, लेिकन ऐसे उपयोग केवल वैǒािनक उȞेʴ (Ůयोजनो)ं के िलए हœ [   ] 
5. मœ उपरोƅ अȯयन मŐ भाग लेने के िलए सहमत šं। [ ] 
 
िवषय / कानूनी ŝप से ˢीकायŊ के हˑाƗर (या अंगूठे की छाप) या Ůितिनिध: 
तारीख: _____/_____/______ 
हˑाƗरकताŊ का नाम: _________________________________ 
अɋेषक के हˑाƗर: _________________________________ 
तारीख: _____/_____/______ 
अȯयन अɋेषक का नाम: _____________________________ 
गवाह की हˑाƗर या अंगूठे का धारणा: ____________________ 
तारीख: _____/_____/_______ 
गवाह का नाम और पता: _______________________________ 
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APPENDIX - (iv) 
DATA COLLECTION SHEET 
STUDY TITLE : Case – Control study for Ocular surface risk factors in microbial keratitis 
 
DATE :____/_____/_____                                                                                    HOSPITAL 
NUMBER: __________  
NAME : _______________________                                      AGE :____                           
                                                                                                   SEX : MALE / FEMALE 
ADDRESS : 
_____________________________________________________________________________
___________________________________________________________________ 
CONTACT NUMBER: ___________________                                                       
HISTORY:  
 Eye involved (cases) : RIGHT / LEFT 
 History of trauma to eye  
 Previous episode of similar problem 
 History of ocular and intraocular surface surgeries in any of the eyes 
 History of Hansen’s disease 
 Contact lens wear 
 Use of any drops last 6 hours 
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 History of chronic use of any eye-drops e.g. anti-glaucoma treatment, lubricants 
 H/O diabetes mellitus, duration and treatment on 
 
 
SYMPTOMS : 
VISUAL ACUITY : 
CLINICAL EXAMINATION : 
TEST RIGHT EYE  LEFT EYE  COMMENTS (if any) 
Corneal sensation    
Schirmers 1    
Schirmers 2    
TBUT    
Blepharitis Yes / No Yes / No  
Meibomitis  Yes / No Yes / No  
    
 
 
 
 
 
 
115 
 
APPENDIX - (v) – DATA 
 
Serial 
No. 
Hosp 
No. Name Age Sex DM 
Affected 
eye 
Corneal 
sensation 
CASES             RE LE 
A1 630555S GOWRI 25 F N RE 55 60    
A2 631845S PALANI 44 M N LE 55 50    
A3 633356S KAVITHA 40 F N LE 50 55    
A4 633377S SUBRAMANI 54 M Y LE 60 50    
A5 529442S STANLEY JONES 53 M N RE 60 60    
A6 227768S SELVI 44 F N LE 60 60    
A7 600796S SULOCHANA 60 F N RE NA 45    
A8 635189S KANNAN 33 M N LE 50 40    
A9 600805S JAYASHANKAR 42 M N LE 60 50    
A10 636954S MANI 52 M N RE 50 55    
A11 637800S MOHAN 44 M Y LE 55 NA 
A12 600878S MOHANRAJ 27 M N LE 60 50    
A13 637800S CHINNADURAI 51 M N LE 60 50    
A14 638514S VEL 42 M N LE 60 55    
A15 600909S RANGANATHAN 60 M Y LE 60 55    
A16 639148S SRIPATHI 42 M Y LE 55 55    
A17 639886S VENKATESAN.P 57 M Y LE 55 55    
A18 582186S SADAGOPAN 70 M Y RE 50 55    
A19 640788S KILIYAMMA 57 M N LE 55 55    
A20 640287S BHARATHI 38 F N LE 60 55    
A21 640896S 
DHANANJAY 
REDDY 64 M Y RE 45 50    
A22 641959S MOHANA 35 F N RE NA 55    
A23 641960S NITHILA 54 F N LE 55 55    
A24 642574S GOVINDHAN 35 M N LE 60 55    
A25 644657S PRABHU 26 M N LE 55 50    
A26 644359S PANEER SELVAM 70 M N LE 55 55    
A27 645603S SARALA 39 F N LE 55 50    
A28 601138S SUBHASH 65 M N RE NA 55    
A29 646655S JAYALAKSHMI 50 F N RE 50 50    
A30 649583S SARAN RAJ 31 M N LE 60 50    
A31 649997S BOOPATHY 52 M Y LE 50 55    
A32 602042S SATHEESH 28 M N LE 45 50    
A33 651877S LAKSHMI 30 F N LE 55 50    
A34 602091S RAMAN 21 M N LE 60 50    
A35 653531S MUNUSWAMY 32 M N LE 60 50    
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A36 653747S MANORMANI 45 F N LE 50 NA 
A37 654206S VENKATESAN 49 M N LE 60 50    
A38 654393S RAJAMMAL 61 F N RE NA 60    
A39 654785S GOUTHAM 26 M N RE 60 60    
A40 381398S GURUBANANDAN 42 M Y RE 60 60    
A41 655272S KALA 57 M N LE 50 45    
A42 655291S RAJKUMAR 24 M N LE 60 60    
A43 655496S KUPAMMA 47 F N LE 60 25    
A44 656014S VENKATESULU 41 M N LE 55 50    
A45 656615S VENKATESAN M 39 M N RE 55 60    
A46 656616S PALANI 41 M N RE 55 50    
A47 657421S MURUGAN 50 M N LE 60 50    
A48 602294S ANANDHAN.G 40 M N LE 60 50    
A49 658568S ANANDAN .P 50 M N RE 40 50    
A50 659560S PACHIAPPAN 45 M N LE 60 50    
A52 659560S DILLI GANAPATHY 31 M N RE 45 55    
A52 660672S RADHA.P 51 F N RE 55 60    
A53 660760S VISHWA 23 M N LE 60 55    
A54 661132S THULASI  35 F N RE 55 60    
A55 602382S AKRAM 25 M N RE 55 50 
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Meibomitis Blepharitis Schirmers 1 
Schirmers with 
anaesthesia TBUT 
RE LE RE LE RE LE RE LE RE LE 
N N N N 25 20 21 17 7 >10 
Y Y N N 9 21 7 13 7 2 
N Y N Y 35 35 35 35       >10 NA 
N N Y Y 10 35 12 18 7 NA 
N N N N 20 3 13 4 >10 >10 
Y Y Y Y 27 35 22 24 >10 >10 
Y Y N N 35 30 26 21 NA 3 
N N Y Y 35 26 12 15 >10 NA 
Y Y Y Y 7 13 4 8 4 5 
Y Y Y Y 35 35 25 18 4 7 
Y Y Y Y 28 35 13 13 8 NA 
Y Y N N 13 32 4 16 >10 >10 
N N N N 35 35 35 30 >10 2 
N Y N N 35 35 19 19 >10 2 
N N N N 5 22 5 15 >10 8 
N N Y Y 22 35 20 25 >10 4 
N N N N 20 35 9 20 >10 8 
N N Y Y 30 33 27 30 4 5 
Y Y Y Y 25 35 7 30 >10 >10 
N N Y Y 6 35 7 18 7 4 
Y Y Y Y 20 7 10 4 NA 3 
Y N N N 15 35 8 21 NA >10 
N Y N Y 25 25 22 20 >10 5 
N N N Y 35 35 20 35 >10 >10 
Y Y Y Y 8 9 7 4 6 8 
Y Y Y Y 7 7 4 4 7 7 
Y Y Y Y 9 8 7 7 4 5 
N N Y Y NA 33 NA 21 NA >10 
Y Y Y Y 2 3 2 1 6 4 
N Y N N 35 35 27 23 >10 >10 
N N N N 7 13 5 8 7 >10 
N N N N 7 35 2 22 4 7 
N N N N 5 21 4 7 6 9 
N N N N 10 35 4 9 >10 9 
N N N N 19 23 17 22 >10 NA 
N N Y Y 33 35 30 35 >10 NA 
N N N N 9 33 7 13 7 5 
N N Y Y 30 33 19 25 5 4 
Y Y Y Y 30 6 8 4 6 6 
Y Y Y Y 22 6 6 3 1 9 
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Y Y N N 3 35 2 18 7 4 
N N N N 1 15 1 5 4 4 
N N N N 10 35 3 15 7 2 
Y Y Y Y 7 35 4 15 7 4 
Y Y N N 35 35 32 32 >10 >10 
N N Y Y 35 35 35 35 6 >10 
Y Y N N 30 35 25 20 >10 NA 
N N N N 35 31 18 17 >10 >10 
Y Y N N 33 35 23 24 NA 7 
N N N N 13 35 10 15 6 NA 
N N N N 35 8 23 7 NA >10 
Y Y Y Y 28 23 25 21 NA 4 
N N N N 33 35 15 19 >10 NA 
Y Y Y Y 35 6 18 5 NA 4 
N N N N 35 35 17 13 >10 >10 
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Serial 
No. Hosp No Name Age Sex DM 
Corneal 
sensation 
CONTROLS           RE LE 
B1 658754S TANUJA PAL 22 F N 60 60 
B2 634766S LITON CHANDRA 41 M N 60 60 
B3 631884S VENDA 40 F N 55 60 
B4 302952S DEVASIGAMANI 52 M Y 55 55 
B5 662597S MD EKRAM KHAN 54 M N 60 60 
B6 635078S SABIRA 41 F N 60 60 
B7 637084S NASRIN BEGUM 56 F N 60 55 
B8 637085S MD AMINULISLAM 34 M N 60 55 
B9 634665S CHANDRASEKARAN 42 M N 60 60 
B10 663295S PALANI K 53 M N 60 60 
B11 661342S ARI BEN SUBHASH 44 M Y 60 60 
B12 655723S RAMESH 30 M N 60 60 
B13 663274S PARTHIBAN 51 M N 55 60 
B14 265329S SATYAMOORTHY 42 M N 60 60 
B15 427036S SITARAM 60 M Y 60 60 
B16 653955S ABDUL LATEEF 43 M Y 60 60 
B17 663314S ASRAF SHEIK 56 M Y 60 60 
B18 532811S 
ESWARAN 
SANKARAN 71 M Y 60 60 
B19 656721S POONGOTHAI 58 F N 60 60 
B20 656723S SUBHASHINI 38 F N 60 60 
B21 383365S JAYAKRISHNA DAS 65 M Y 55 55 
B22 292411S SRIPRIYA 36 F N 60 60 
B23 442338S CHINTAMANI 55 F N 55 45 
B24 593390S PAVAN REDDY 35 M N 60 60 
B25 654987S SURESH 26 M N 55 55 
B26 874948E VASUDEVAN 70 M N 60 60 
B27 481103S DEEPA 41 F N 55 55 
B28 651752S CHANDRASEKARAN 62 M N 60 60 
B29 462823S KUMARI 51 F N 45 45 
B30 663231S SAMIR KUMAR 34 N N 60 60 
B31 661310S KAMARAJ 54 M Y 55 55 
B32 652674S PRAKASH 27 M N 60 60 
B33 660189S DHANALAKSHMI 29 F N 60 60 
B34 655752S SURYAPRADESH 21 M N 60 60 
B35 662565S SYED KABEER 35 M N 60 60 
B36 413426S INDUVATHI 41 F N 60 60 
B37 660277S ALAMGIR SEKH 49 M N 50 50 
B38 663325S SULOCHANA 60 F N 60 60 
B39 662140S KABINDRANATH 28 M N 60 60 
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B40 660525S SAMBASIVAM C.M 41 M Y 60 60 
B41 656147S JOTHI 56 F N 60 60 
B42 655706S VIJAI 23 M N 60 60 
B43 470143S SHAHEENA 46 F N 60 60 
B44 383968S PAZHANI 43 M N 60 60 
B45 923596E INBAKUMAR 38 M N 60 60 
B46 477668S BASHEER AHMED 42 M N 60 60 
B47 662540S AKRAMUL HODUE 47 M N 60 60 
B48 728251E RAMESH 40 M N 60 60 
B49 663239S JEEVA 50 M N 60 60 
B50 481101S MURALIDARAN 46 M N 60 60 
B51 663243S MD ALI HASAN 33 M N 60 60 
B52 661329S SAMPOORNAMMA 50 F N 55 55 
B53 663331S 
SAMIRAN 
BARAKNDAJ 24 M N 60 60 
B54 662061S SHARMILA SAW 38 F N 55 60 
B55 663319S DHARANIVASAN 27 M N 55 55 
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Meibomitis Blepharitis 
Schirmers 
1 
Schirmers with 
anaesthesia TBUT 
RE LE RE LE RE LE RE LE RE LE 
N N N N 35 33 20 17 >10 >10 
N N N N 13 22 12 21 >10 >10 
Y Y Y Y 20 30 18 19 >10 >10 
N N N N 7 13 6 10 7 >10 
N N N N 20 19 11 13 12 13 
N N N N 10 5 2 4 6 6 
N N N N 19 14 15 13 >10 9 
Y Y N N 17 27 15 15 >10 >10 
Y Y Y Y 16 17 15 15 >10 8 
N N N N 25 30 21 18 14 13 
N N N N 18 24 6 6 >10 >10 
N N N N 35 35 25 25 >10 >10 
N N N N 35 35 20 21 11 12 
Y Y N N 20 20 12 10 >10 >10 
N N N N 25 21 20 15 14 13 
Y Y N N 33 35 15 18 >10 >10 
N N N N 29 35 17 20 11 12 
Y Y Y Y 20 30 18 16 6 5 
N N N N 9 4 8 4 8 6 
N N N N 35 33 15 13 >10 >10 
Y Y N N 22 25 18 21 >10 >10 
N N N N 32 35 18 30 13 15 
N Y N Y 16 17 15 15 >10 >10 
N N N N 25 22 15 17 15 12 
N N N N 12 13 3 8 8 8 
N N Y Y 13 18 7 13 4 6 
N N Y Y 7 8 4 8 7 4 
N N N N 20 30 20 23 6 7 
N N N N 15 15 13 13 6 7 
N N N N 15 17 11 14 >10 >10 
Y Y Y Y 17 20 13 11 12 10 
Y Y Y Y 18 23 8 10 5 7 
N N N N 32 35 20 31 >10 >10 
N Y Y Y 25 35 20 30 6 9 
N N N N 20 18 11 14 12 13 
N N N N 20 30 18 22 9 8 
Y Y N N 10 10 9 7 4 6 
N N N N 35 35 18 17 12 12 
N N N N 17 25 11 17 14 16 
N N N N 35 35 20 25 >10 >10 
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N N N N 33 17 9 7 >10 >10 
N N N N 35 35 35 35 >10 >10 
Y Y N N 15 18 13 17 8 10 
N N N N 25 20 13 7 9 10 
Y Y N N 20 20 15 15 >10 >10 
Y Y N N 20 25 19 20 >10 14 
N N N N 24 22 15 17 11 10 
N N N N 20 15 10 12 >10 >10 
N N N N 25 21 15 13 12 11 
N N Y Y 27 25 14 19 >10 >10 
N N N N 35 32 17 14 13 11 
N N N N 22 25 20 24 >10 >10 
N N N N 35 35 25 27 12 13 
N N N N 15 17 15 15 12 14 
N N N N 35 35 15 13 11 11 
 
